{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-014464","form_type":"8-K","ticker":"VKTX","cik":"0001607678","company_name":"Viking Therapeutics, Inc.","filed_at":"2025-02-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.177087+00:00","generated_at":"2026-05-27T02:42:38.864844+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Viking Therapeutics reports FY2024 net loss $110M; cash $903M; Phase 3 VK2735 planned 2Q25","bullets":["Net loss $110.0M ($1.01 per share) for FY2024, compared to net loss $85.9M ($0.91 per share) in 2023.","Cash, cash equivalents and short-term investments of $903M as of Dec 31, 2024, up from $362M a year earlier.","Initiation of Phase 3 studies for subcutaneous VK2735 in obesity planned for 2Q25 after FDA End-of-Phase 2 meeting.","Phase 2 VENTURE-Oral trial of VK2735 tablet underway in ~280 obese subjects; data expected 2H25.","Phase 2b VOYAGE in MASH: VK2809 showed MASH resolution rates up to 75% vs 29% placebo, and fibrosis improvement."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-014464","json":"https://secwatch.observer/filing/0000950170-25-014464.json","markdown":"https://secwatch.observer/filing/0000950170-25-014464.md","text":"https://secwatch.observer/filing/0000950170-25-014464.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1607678/000095017025014464/0000950170-25-014464-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1607678/000095017025014464/vktx-20250205.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T02:42:38.864844+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}